Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System

BACKGROUND: Infigratinib is a fibroblast growth factor receptor (FGFR)-specifc tyrosine kinase inhibitor indicated for the treatment of patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma. However, few studies have been conducted to evaluated the safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Dehua, Long, Xiaoqing, Zhou, Jiping, Wang, Jisheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676333/
https://www.ncbi.nlm.nih.gov/pubmed/37700091
http://dx.doi.org/10.1007/s40268-023-00439-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676333/
https://www.ncbi.nlm.nih.gov/pubmed/37700091
http://dx.doi.org/10.1007/s40268-023-00439-1

Ejemplares similares